Amgen reaches billion-dollar licensing deal with Japanese firm
Amgen announced an agreement June 1 with Kyowa Kirin, a Japanese pharmaceutical company, to jointly develop and commercialize a human monoclonal antibody that Kyowa Kirin is developing to treat atopic dermatitis and other autoimmune diseases. The deal could be worth $1.25 billion or more. Amgen will led the development, manufacturing and commercialization for the treatment, Read More →
Dubroff: Wind, batteries could replace nuclear power on Central Coast
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Our View: Recovery is in the air for Central Coast tourism
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen gets FDA approval for potential billion-dollar drug
Thousand Oaks-based Amgen won approval from the U.S. Food and Drug Administration on May 28 for its latest oral drug treatment, Lumakras, potentially adding another huge market for one of the largest biotech firms in the world. According to the Wall Street Journal, Amgen will charge $17,900 a month for the drug and analyst think Read More →
Lumber shortages drive building costs through the roof
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Public health meets private sector with Charity Dean’s new venture
Months into the COVID-19 pandemic, Dr. Charity Dean realized a harsh reality. She was then assistant director of the California Department of Public Health, and she knew the state and nation were literally in a do-or-die situation. “As a local health officer, I learned painfully that no one is coming to save me,” Dean, who Read More →
QAD stock rises after earnings beat
QAD, a Santa Barbara-based cloud software company for the manufacturing industry, beat analysts’ expectations with its earning for the first quarter of its 2021-22 fiscal year on May 26. QAD’s net income for the quarter was $1.8 million, or 7 cents per share, compared to a loss of $410,000 in the same quarter a year Read More →
